Loading patent…
AssigneesInstitut National De La Sante Et De La Recherche Medicale (Inserm), Universite de Paris X1 Paris Sud
InventorsEric Rubinstein, Céline Greco, François Le Naour, Claude Boucheix
Estimating the term…
The present disclosure relates to a Co-029 inhibitor for inhibiting the migration of cancer cells which express Co-029. The disclosure relates to a Co-029 inhibitor for the treatment of cancer and/or the prevention of cancer metastasis and pharmaceutical compositions comprising said inhibitor and provides Co-029 antibodies. The disclosure provides a method for predicting the response of a patient afflicted with or susceptible to be afflicted with cancer to a medical treatment with a Co-029 inhibitor, a method for diagnosing a cancer in a patient and a method for predicting the survival in a cancer patient.
A pharmaceutical composition comprising an inhibitor of human Co-029, wherein said inhibitor is an antibody which contains the CDRs of an antibody obtainable from the hybridoma accessible under CNCM deposit number I-4046 or I-4047 and a pharmaceutically acceptable carrier.
An isolated Co-029 antibody directed against human Co-029 which is obtainable from the hybridoma accessible under CNCM deposit number I-4046 or I-4047.
An isolated Co-029 antibody directed against human Co-029 which comprises the six complementarity determining region (CDR) sequences of an antibody which is obtainable from the hybridoma accessible under CNCM deposit number I-4046 or the six complementarity determining region (CDR) sequences of an antibody which is obtainable from the hybridoma accessible under CNCM deposit number I-4047.
Dependencies are inferred from the claim text.